ライフサイエンスコーパス: ventricular dilation

1 ogressive symptomatic heart failure and left ventricular dilation.

2 ic regurgitation complicated by extreme left ventricular dilation.

3 ile function, decreased work capability, and ventricular dilation.

4 h, associated with eccentric hypertrophy and ventricular dilation.

5 However, MMPi reduced ventricular dilation.

6 city and contractile function and attenuated ventricular dilation.

7 racterized by impaired systolic function and ventricular dilation.

8 Only L-NAME caused right ventricular dilation.

9 er (91% vs. 65%, p = 0.04), and severe right ventricular dilation (39% vs. 0%, p = 0.013).

10 The phenotype consisted of left ventricular dilation (68%), systolic dysfunction (46%),

11 Mitral regurgitation (MR) causes ventricular dilation, a blunted myocardial force-frequen

12 on of an MMP inhibitor attenuates early left ventricular dilation after experimental MI in mice.

13 ized mice to cardiac decompensation and left ventricular dilation after long-term stimulation by pres

14 Cardiac rupture is preceded by left ventricular dilation and a severe decrease in cardiac co

15 ed the clinical manifestation of human ARVC: ventricular dilation and aneurysm, cardiac fibrosis, car

16 ed CD34+ cells (CD34(Shh)) protected against ventricular dilation and cardiac functional declines ass

17 Echocardiography revealed ventricular dilation and decreased cardiac function, whi

18 ar (LV) fractional shortening accompanied by ventricular dilation and decreased phosphocreatine to AT

19 c analysis demonstrated the presence of left ventricular dilation and decreased systolic function in

20 ion with 3 months follow-up resulted in left ventricular dilation and dysfunction in both wild-type a

21 systole, left ventricular dysfunction, right ventricular dilation and dysfunction, and a large perica

22 ardial iNOS expression, cardiac hypertrophy, ventricular dilation and dysfunction, and fibrosis, wher

23 tion and angiogenesis, thereby limiting left ventricular dilation and dysfunction.

24 to CD8KO mice, MHCIIKO mice did not develop ventricular dilation and dysfunction.

25 e receptor (AR) pathways in hearts with left ventricular dilation and dysfunction.

26 ion of recombinant GDF15 protein, attenuated ventricular dilation and heart failure in muscle lim pro

27 ac filling pressures may lead to progressive ventricular dilation and heart failure progression.

28 lly followed by scar formation with eventual ventricular dilation and heart failure.

29 farction (MI) is associated with progressive ventricular dilation and heart failure.

30 re 85+/-1 versus 66+/-2 mm Hg; P<0.01), left ventricular dilation and hypertrophy (mass/body weight 4

31 iotensin-converting enzyme inhibition limits ventricular dilation and hypertrophy and improves surviv

32 Ventricular dilation and hypertrophy in addition to dete

33 mmunocomplexes followed by cardiomegaly with ventricular dilation and hypertrophy, ultimately succumb

34 athic dilated cardiomyopathy had evidence of ventricular dilation and hypokinesis, with a left ventri

35 Mutant G202R and A592E mice exhibited left ventricular dilation and impaired function with specific

36 ation of the heart, as well as in attenuated ventricular dilation and improved cardiac function.

37 more than wild type, along with greater left ventricular dilation and increased fibrosis, apoptosis,

38 y 14, echocardiography showed increased left ventricular dilation and infarct expansion.

39 nges were associated with reductions in left ventricular dilation and left ventricular mass measured

40 Left ventricular dilation and loss of heart function was prec

41 during atrial arrhythmia are those with left ventricular dilation and low atrial ejection fraction ac

42 ially with an epicardial patch to limit left ventricular dilation and mitral regurgitation.

43 3+, fibrillation (vs. type I flutter), left ventricular dilation and mitral valve area < 2.0 cm2.

44 hat IL-1beta and TNF-alpha may contribute to ventricular dilation and myocardial failure by promoting

45 Left ventricular dilation and myocardial fibrosis are associa

46 hallium lung-to-myocardial ratio (L/M), left ventricular dilation and perfusion defect site were comp

47 Lung uptake, left ventricular dilation and perfusion defect size show good

48 The engrafted human myocardium attenuated ventricular dilation and preserved regional and global c

49 car with newly formed myocardium, attenuated ventricular dilation and prevented the chronic decline i

50 s remodeling of the myocardium, resulting in ventricular dilation and pump dysfunction.

51 In mice with left ventricular dilation and pump failure attributable to pr

52 graphy of homozygous mutant mice showed left ventricular dilation and reduced contractile function at

53 Systolic heart failure is characterized by ventricular dilation and reduced ejection fraction, and

54 ted myocytes was depressed and preceded left ventricular dilation and reduced fractional shortening.

55 +cell hearts exhibited attenuation of global ventricular dilation and reduced septum-to-free wall dia

56 lso enhance late survival by preventing left ventricular dilation and reducing arrhythmias, independe

57 ath and low rate of reintervention for right ventricular dilation and residual outflow tract obstruct

58 Proapoptotic Nix caused ventricular dilation and severe contractile depression i

59 s of afterload reduction for preventing left ventricular dilation and symptom onset in aortic regurgi

60 ilated cardiomyopathy, characterized by left ventricular dilation and systolic dysfunction with signs

61 Left ventricular dilation and the presence of late gadolinium

62 Heterozygous patients exhibit left ventricular dilation and ventricular arrhythmias.

63 endent increase in cardiac hypertrophy, left ventricular dilation, and adverse left ventricular remod

64 entricular ejection fraction <40%, mild left ventricular dilation, and no symptoms of heart failure (

65 developed greater cardiac hypertrophy, left ventricular dilation, and reduced contractile function.

66 eccentric hypertrophy, substantial fibrosis, ventricular dilation, and reduced fractional shortening,

67 r rates of cardiac rupture, more severe left ventricular dilation, and suppressed ejection fraction c

68 ascular-specific expression (vGOF) show left ventricular dilation as well as less-markedly increased

69 db/db animals, dbTSP mice had increased left ventricular dilation associated with mild nonprogressive

70 Untreated sheep developed left ventricular dilation at 3 months, with global dysfunctio

71 , congestive heart failure, and greater left ventricular dilation at diagnosis were independently ass

72 uld not be attributed to differences in left ventricular dilation because end-diastolic volumes incre

73 sion maintenance and increased resistance to ventricular dilation) but also for a potentially deleter

74 Both NOS inhibitors led to left ventricular dilation, but PE did not.

75 ice, loss of cMyBP-C has been linked to left ventricular dilation, cardiac hypertrophy, and systolic

76 age, heterozygous individuals developed left ventricular dilation, contractile dysfunction, and episo

77 decline in cardiac function, attenuated left ventricular dilation, decreased infarct size, and reduce

78 exacerbated, as indicated by increased left ventricular dilation, decreased ventricular function, in

79 h adverse outcomes are characterized by left ventricular dilation despite CRT.

80 ed in aortic regurgitation with extreme left ventricular dilation (diastolic dimension >/= 80 mm), bu

81 Extreme left ventricular dilation due to aortic regurgitation is obse

82 egurgitation (AR) focus on symptoms and left ventricular dilation/dysfunction.

83 (40% higher after 30 days) and stronger left ventricular dilation early after MI.

84 ventricular power, P=0.0002), and increased ventricular dilation (end-diastolic volume, P=0.01).

85 ks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance,

86 erload developed less hypertrophy and showed ventricular dilation, impaired contractile function, inc

87 Trpc6 deletion also ameliorated left ventricular dilation, improved cardiac function, and ten

88 eart failure therapy indexed by reduced left ventricular dilation, improved left ventricular ejection

89 p to day 56 after MI revealed increased left ventricular dilation in CD4 KO compared with WT mice.

90 iction (TAC) for 6 weeks caused greater left ventricular dilation in G6PDX mice than wild-type mice.

91 iography showed significantly increased left ventricular dilation in male IL-13(-/-) compared with WT

92 ography at day 1 demonstrated increased left ventricular dilation in OIM/OIM animals.

93 Advanced age is a predictor of death and ventricular dilation in patients with MI; however, the c

94 -/-) animals lack a corpus callosum and show ventricular dilation indicating early hydrocephalus.

95 Therefore, extreme left ventricular dilation is not a contraindication to operat

96 severe cardiac abnormalities, including left ventricular dilation, left ventricular mass reduction, a

97 Left ventricular dilation may predispose to alterations of re

98 viable myocardium after infarction, limiting ventricular dilation, myocardial loading, and cardiac hy

99 These factors limit ventricular dilation, myocardial loading, cardiac hypert

100 However, ventricular dilation, myocyte hypertrophy and death, and

101 Ultimately, a phase develops where ventricular dilation occurs in an attempt to limit the r

102 muscle disorder characterized by atrial and ventricular dilation often with relative wall thinning,

103 gurgitation is indicated if symptoms or left ventricular dilation or dysfunction occur.

104 It can be associated with left ventricular dilation or hypertrophy, systolic or diastol

105 ntriculomegaly due to either posthemorrhagic ventricular dilation or periventricular white matter los

106 of increased wall thickness, local or global ventricular dilation, or dysfunction also involved the R

107 cular ejection fraction (p = 0.006) and left ventricular dilation (p = 0.015) at the follow-up evalua

108 tolic dimension >/= 80 mm), but extreme left ventricular dilation raises concern about irreversible l

109 protein composition, loss of cardiomyocytes, ventricular dilation, reduced pump function, and ultimat

110 particularly severe myocardial fibrosis with ventricular dilation, reminiscent of the dilated cardiom

111 ions in ventricular performance, and greater ventricular dilation than alpha1C(+)/(+) controls.

112 ated cardiomyopathy is characterised by left ventricular dilation that is associated with systolic dy

113 d cellular hypertrophy, are concomitant with ventricular dilation, thinning of the wall and cardiac d

114 nd indicates severe symptoms (hydrocephalus, ventricular dilation), treatment is continued until deli

115 rapidly progressive cardiomyopathy with left ventricular dilation, wall thinning, and reduced systoli

116 Left ventricular dilation was associated with hemodynamic cha

117 Ventricular dilation was associated with marked reductio

118 Right ventricular dilation was noted in 40 subjects (74.1%), w

119 Ventricular dilation was observed in all BSN-dosed mice.

120 Left ventricular dilation was reduced in the GH-treated versu

121 Preoperatively, extreme left ventricular dilation was seen only in male patients and

122 rity of preoperative cardiac dysfunction and ventricular dilation were not.

123 sis of embryos revealed evidence of profound ventricular dilation, which likely resulted in embryonic

124 l infarction (MI) developed progressive left ventricular dilation with dysfunction and HF at 4 wk pos

125 roduced spontaneous eccentric remodeling and ventricular dilation with heart failure.

126 infarction and exhibit significantly limited ventricular dilation with sustained and remarkably enhan